Eisai to divest rights for two therapies to Kaken

02 Apr 2024
www.pharmaceutical-technology.com
Drug ApprovalPhase 3AcquisitionLicense out/inBiosimilar
Eisai to divest rights for two therapies to Kaken
Preview
Source: Pharmaceutical Technology
Eisai will continue to focus on creating and delivering products to target disease. Credit: mkfilm/Shutterstock.com.
Eisai has signed an agreement for the divestiture of rights for Merislon and MyonalMyonal, two of its long-standing products in Japan, to Kaken Pharmaceutical.
The transaction is valued at Y3.8bn ($25.10m).
Merislon treats vertigo and equilibrium disturbances and Myonal is a muscle relaxant, which patients have used since their respective launches in 1969 and 1983.
The agreement stipulates that Eisai will complete the transfer of marketing capabilities by March 2025, followed by manufacturing and marketing approval transfer.
The deal will not impact Eisai’s consolidated financial forecast for 31 March 2024.
See Also:
China accepts Innovent-HUTCHMED’s endometrial cancer therapy NDA
Eisai to divest rights for two therapies to Kaken
Preview
Source: Pharmaceutical Technology
Magazine: What’s next for AAV gene therapies in 2024?
Eisai to divest rights for two therapies to Kaken
Preview
Source: Pharmaceutical Technology
The company stated: “Eisai has determined that divesting rights for these products to Kaken, which has strengths in the products’ disease areas, is the optimal choice to ensure they continue contributing to a greater number of patients.”
Eisai will continue to focus on creating and delivering products to target diseases with higher unmet medical needs such as neurology, oncology and global health.
Kaken is a research and development-driven pharmaceutical company that focuses on orthopaedics and dermatology.
Earlier this month, Eisai received approval for the amyloid beta-directed antibody Leqembi (lecanemab-irmb) in China to treat mild cognitive impairment associated with Alzheimer’s disease (AD) and mild AD dementia.
Leqembi, developed in partnership with BioArctic, will be available in the region in the third quarter of 2024. The approval in China is based on the international Phase III Clarity AD study.
Eisai will be responsible for distribution and information provision through expert medical representatives.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.